Display options
Cite
Denisova GF, Denisov DA, Bramson JL. Applying bioinformatics for antibody epitope prediction using affinity-selected mimotopes - relevance for vaccine design. Immunome Res. 2010;6:S6doi: 10.1186/1745-7580-6-S2-S6.
Denisova, G. F., Denisov, D. A., & Bramson, J. L. (2010). Applying bioinformatics for antibody epitope prediction using affinity-selected mimotopes - relevance for vaccine design. Immunome research, 6S6. https://doi.org/10.1186/1745-7580-6-S2-S6
Denisova, Galina F, et al. "Applying bioinformatics for antibody epitope prediction using affinity-selected mimotopes - relevance for vaccine design." Immunome research vol. 6 (2010): S6. doi: https://doi.org/10.1186/1745-7580-6-S2-S6
Denisova GF, Denisov DA, Bramson JL. Applying bioinformatics for antibody epitope prediction using affinity-selected mimotopes - relevance for vaccine design. Immunome Res. 2010 Nov 03;6:S6. doi: 10.1186/1745-7580-6-S2-S6. PMID: 21067548; PMCID: PMC2981875.
Copy Download .nbib Format: NLM
Share it on

Immunome Res. 2010 Nov 03;6:S6. doi: 10.1186/1745-7580-6-S2-S6.

Applying bioinformatics for antibody epitope prediction using affinity-selected mimotopes - relevance for vaccine design.

Immunome research

Galina F Denisova, Dimitri A Denisov, Jonathan L Bramson

Affiliations

  1. Department of Pathology and Molecular Medicine, Centre for Gene Therapeutics, McMaster University, 1200 Main Street West, Hamilton, Ontario, Canada, L8N 3Z5. [email protected].

PMID: 21067548 PMCID: PMC2981875 DOI: 10.1186/1745-7580-6-S2-S6

Abstract

To properly characterize protective polyclonal antibody responses, it is necessary to examine epitope specificity. Most antibody epitopes are conformational in nature and, thus, cannot be identified using synthetic linear peptides. Cyclic peptides can function as mimetics of conformational epitopes (termed mimotopes), thereby providing targets, which can be selected by immunoaffinity purification. However, the management of large collections of random cyclic peptides is cumbersome. Filamentous bacteriophage provides a useful scaffold for the expression of random peptides (termed phage display) facilitating both the production and manipulation of complex peptide libraries. Immunoaffinity selection of phage displaying random cyclic peptides is an effective strategy for isolating mimotopes with specificity for a given antiserum. Further epitope prediction based on mimotope sequence is not trivial since mimotopes generally display only small homologies with the target protein. Large numbers of unique mimotopes are required to provide sufficient sequence coverage to elucidate the target epitope. We have developed a method based on pattern recognition theory to deal with the complexity of large collections of conformational mimotopes. The analysis consists of two phases: 1) The learning phase where a large collection of epitope-specific mimotopes is analyzed to identify epitope specific "signs" and 2) The identification phase where immunoaffinity-selected mimotopes are interrogated for the presence of the epitope specific "signs" and assigned to specific epitopes. We are currently using computational methods to define epitope "signs" without the need for prior knowledge of specific mimotopes. This technology provides an important tool for characterizing the breadth of antibody specificities within polyclonal antisera.

References

  1. Expert Opin Biol Ther. 2006 Feb;6(2):177-87 - PubMed
  2. Protein Eng Des Sel. 2010 Apr;23(4):279-88 - PubMed
  3. PLoS One. 2009;4(4):e5309 - PubMed
  4. Microbiol Immunol. 2008 Apr;52(4):209-15 - PubMed
  5. Cell Mol Life Sci. 2008 Apr;65(7-8):1059-72 - PubMed
  6. Clin Diagn Lab Immunol. 2001 Jan;8(1):150-60 - PubMed
  7. J Infect Dis. 1997 Nov;176(5):1180-7 - PubMed
  8. J Immunol. 2002 Dec 15;169(12):6992-9 - PubMed
  9. Anal Sci. 2009 Jan;25(1):41-9 - PubMed
  10. J Mol Biol. 2003 Nov 14;334(1):87-101 - PubMed
  11. Mol Biotechnol. 2010 Oct;46(2):105-12 - PubMed
  12. Methods Mol Biol. 2007;352:205-19 - PubMed
  13. FASEB J. 2010 Jul;24(7):2201-10 - PubMed
  14. Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12297-302 - PubMed
  15. Trends Microbiol. 2001 Sep;9(9):445-51 - PubMed
  16. EMBO J. 1994 May 1;13(9):2236-43 - PubMed
  17. Biochemistry. 1993 May 18;32(19):5083-92 - PubMed
  18. J Virol. 1995 Sep;69(9):5294-9 - PubMed
  19. Eur J Immunol. 2007 Feb;37(2):501-15 - PubMed
  20. J Mol Biol. 1998 Aug 7;281(1):183-201 - PubMed
  21. Methods. 1996 Jun;9(3):465-72 - PubMed
  22. Methods Mol Biol. 1998;87:195-208 - PubMed
  23. Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8691-5 - PubMed
  24. FASEB J. 2006 Sep;20(11):1762-74 - PubMed
  25. J Virol. 1998 Mar;72(3):2040-6 - PubMed
  26. Nat Rev Genet. 2010 Jan;11(1):31-46 - PubMed
  27. Drug Discov Today. 2006 Oct;11(19-20):911-6 - PubMed
  28. Nat Med. 2001 Nov;7(11):1225-31 - PubMed
  29. Mol Immunol. 1986 Jul;23(7):709-15 - PubMed
  30. Methods Mol Biol. 2005;310:197-216 - PubMed
  31. J Virol. 2006 Dec;80(24):12149-59 - PubMed
  32. Gene. 1993 Jun 15;128(1):51-7 - PubMed
  33. Cancer Chemother Pharmacol. 2000;46 Suppl:S37-42 - PubMed
  34. Vaccine. 2005 Feb 18;23(13):1559-73 - PubMed
  35. J Immunol Methods. 1998 Jul 1;216(1-2):37-48 - PubMed
  36. FEMS Microbiol Lett. 2010 Jan;302(1):1-7 - PubMed
  37. Mol Immunol. 2008 Nov;46(1):125-34 - PubMed
  38. Mol Immunol. 2009 Jan;46(3):429-36 - PubMed
  39. J Theor Biol. 1973 Oct;41(3):431-9 - PubMed
  40. Biomol Eng. 2001 Sep;18(2):57-63 - PubMed
  41. J Virol. 2001 Jul;75(14):6692-9 - PubMed
  42. Vaccine. 1999 Sep;18(3-4):284-90 - PubMed
  43. J Mol Recognit. 2006 Jan-Feb;19(1):21-9 - PubMed
  44. J Mol Biol. 1996 Oct 11;262(5):732-45 - PubMed
  45. Protein Sci. 2005 Jan;14(1):246-8 - PubMed
  46. J Immunol. 1999 May 15;162(10):6155-61 - PubMed
  47. J Infect Dis. 1997 Oct;176(4):924-32 - PubMed
  48. N Engl J Med. 2007 Nov 8;357(19):1903-15 - PubMed
  49. AIDS Res Hum Retroviruses. 1996 Jul 1;12(10):901-9 - PubMed
  50. J Mol Recognit. 2003 Jan-Feb;16(1):20-2 - PubMed
  51. J Immunotoxicol. 2006 Sep 1;3(3):137-49 - PubMed
  52. Proteomics. 2004 Jul;4(7):1950-8 - PubMed
  53. Appl Microbiol Biotechnol. 2004 Mar;64(1):28-40 - PubMed
  54. Proteins. 2008 Feb 15;70(3):938-49 - PubMed
  55. Cancer J. 2000 May;6 Suppl 3:S208-17 - PubMed
  56. Arch Virol. 2007 Jan;152(1):25-39 - PubMed
  57. J Gen Virol. 2000 Mar;81(Pt 3):729-35 - PubMed
  58. EMBO J. 1998 Jul 1;17(13):3521-33 - PubMed
  59. FASEB J. 2000 Feb;14(2):231-41 - PubMed
  60. AIDS Res Hum Retroviruses. 1997 Dec 10;13(18):1549-59 - PubMed
  61. Protein Eng Des Sel. 2010 Jan;23(1):9-17 - PubMed
  62. Mol Immunol. 2007 Jan;44(4):541-57 - PubMed
  63. Expert Rev Proteomics. 2005 Jun;2(3):421-30 - PubMed
  64. Protein Eng Des Sel. 2004 Feb;17(2):175-82 - PubMed
  65. Dis Aquat Organ. 1998 Nov 30;34(3):167-76 - PubMed
  66. J Mol Biol. 2007 Jun 8;369(3):696-709 - PubMed
  67. Proteins. 2007 Sep 1;68(4):803-12 - PubMed
  68. J Mol Recognit. 2007 Mar-Apr;20(2):75-82 - PubMed
  69. EMBO Rep. 2004 Nov;5(11):1016-20 - PubMed
  70. J Immunol. 2001 Apr 15;166(8):5271-8 - PubMed
  71. Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6335-9 - PubMed
  72. J Am Chem Soc. 1975 Nov 12;97(23):6830-8 - PubMed
  73. Gene. 1993 Jun 15;128(1):21-7 - PubMed
  74. Anal Biochem. 2005 Jan 15;336(2):145-57 - PubMed

Publication Types